The new BTK-PROTAC induced rapid tumor regression of BTK-mutant-bearing lymphoma xenografts with limited signs of toxicity and showed even higher inhibitory activity when combined with Lyn, PI3K and Syk inhibitors [136]. Here, BTK is linked to lymphoma.